Attitudes About Mandated Coverage of Birth Control Medication and Other Health Benefits in a US National Sample

Access to contraception improves maternal and child health. The Patient Protection and Affordable Care Act (ACA) requires most private health insurance plans to cover contraception without a shared patient cost to improve access. However, debate continues about applying the contraception coverage mandate to public corporations that object on religious grounds; the US Supreme Court is reviewing the ACA’s contraceptive coverage requirement. We assessed attitudes about mandated coverage of birth control medications.

Methods | A cross-sectional survey was administered in November 2013. The survey used the online KnowledgePanel (GfK Custom Research North America), a national panel established through probability sampling of the civilian, noninstitutionalized US population (aged ≥18 years). Respondents were asked, “Do you think that all health plans in the United States should be required to include coverage for the following services: birth control medications, preventive services like mammograms and colonoscopies, recommended vaccinations, preventive screening tests for diabetes and high cholesterol, mental health care, and dental/tooth care including dental screenings and tooth problems?” Possible responses included yes, no, uncertain, and refused to answer. The response rate was determined using RR1 of the American Association for Public Opinion Research.

Descriptive statistics were calculated for all items. χ² Analyses and logistic regression were performed to assess associations between support for birth control medication coverage and demographic factors, applying poststratification sampling weights to draw national inferences (2-sided P < .05 or 95% CI not including the null was significant). Support was defined as answering “yes” and do not support as answering “no” or “uncertain.” Statistical analyses were performed with Stata version 13 (StataCorp). The University of Michigan medical institutional review board declared this study exempt.

Results | The response rate was 61% (2124/3504). Respondents were more likely to be white, older, and have higher levels of education and income than nonrespondents. After applying sampling weights, respondents were 54% female; 64% non-Hispanic white, 16% Hispanic, 12% non-Hispanic black, and 8% non-Hispanic other race. Most respondents (69%; 95% CI, 67%-72%) supported a policy of mandated coverage of birth control medication in health plans. This proportion was significantly lower than the proportion that supported other benefits (Table 1). In multivariable regression analysis, support for mandated coverage of birth control medication was significantly higher among women, non-Hispanic blacks, Hispanics, parents with children younger than 18 years living in the home, and adults with private or public insurance vs comparison groups (Table 2), but was not associated with education or income.

Among a small group (7.8%; 95% CI, 6.6%-9.3%) who supported all benefits except birth control medications, there were significantly higher proportions of men (56% vs 41%, P = .003), individuals older than 60 years (27% vs 10%, P < .001), and individuals without children younger than 18 years living in the home (39% vs 26%, P = .003) compared with those who supported all benefits.

Discussion | Overall, 69% of respondents supported mandated coverage of birth control medications in health plans, with significantly higher odds of support among women, black, and

---

**Table 1. Attitudes About Mandated Coverage of Specific Benefits in Health Plans**

| Do you think that all health plans in the United States should be required to include coverage for the following services? | Respondents, No. (Weighted %) [95% CI] (N = 2124) |
| --- | --- | --- | --- | --- |
| Birth control medications | Yes | 1452 (69) [67-72] | 436 (19) [17-21] | 197 (10) [8-11] | 39 (2) [2-3] |
| Preventive services like mammograms and colonoscopies | 1805 (85) [83-87] | 172 (8) [6-9] | 108 (5) [4-6] | 39 (2) [2-3] |
| Recommended vaccinations | 1780 (84) [82-86] | 183 (8) [7-9] | 114 (5) [4-7] | 47 (3) [2-4] |
| Preventive screening tests for diabetes and high cholesterol | 1753 (82) [80-84] | 194 (9) [7-10] | 131 (6) [5-7] | 46 (3) [2-4] |
| Mental health care | 1605 (77) [75-79] | 254 (11) [9-13] | 231 (11) [9-12] | 34 (2) [1-3] |
| Dental/tooth care including dental cleanings and tooth problems | 1576 (75) [73-77] | 344 (14) [13-16] | 169 (8) [7-10] | 35 (2) [1-3] |

*Statistically different (P < .001) from birth control medications and services in 1 sample test of proportion.

**Statistically different (P = .01) from birth control medications and services in 1 sample test of proportion.
Hispanic respondents. Support for mandated coverage of birth control medication was lower than for other benefits, including services that have prompted public debate (eg, vaccination and mental health services). The small group who supported coverage for services except birth control medication included a higher proportion of persons unlikely to use such coverage.

Findings are potentially limited by lack of information about respondents’ political views, voter record, and religiosity; social desirability bias (minimized by an anonymous, online survey); and cross-sectional design that may not capture rapidly evolving opinions. Potential response bias due to differences between respondents and nonrespondents was addressed by post-stratification weighting and minimized by lack of disclosure of survey content at time of invitation to participate.

In this study, the majority of participants supported universal coverage of birth control medications, as well as mandated coverage of several other services. These results are similar to prior polls describing support for the contraceptive coverage mandate among 61% to 66% of US adults.4-6 In this study, women, black, and Hispanic respondents were more likely to support coverage of birth control medication benefits than men, older respondents, and adults without children younger than 18 years. These findings may inform the ongoing national debate around the contraceptive coverage mandate.

Michelle H. Moniz, MD
Matthew M. Davis, MD, MAPP
Tammy Chang, MD, MPH, MS
Influence of Chronic Kidney Disease on Warfarin Therapy for Atrial Fibrillation

To the Editor Dr Carrero and colleagues1 evaluated the influence of chronic kidney disease (CKD) on the efficacy and safety of warfarin therapy in a population with atrial fibrillation and recent myocardial infarction. Previous studies have found that warfarin, when added to aspirin or dual antiplatelet therapy, is associated with increased risk of major bleeding.2,3 We thus find it surprising that, in this registry-based Swedish investigation, no excess bleeding risk was observed in warfarin users across stages of CKD. Accordingly, the characteristics of the study population deserve careful examination.

Only 21.8% of patients with atrial fibrillation were prescribed warfarin, despite more than 75% of patients having a CHA2DS2 score of 2 or higher, perhaps reflecting stringent selection of patients with low overall bleeding risk. The reasons for withholding warfarin were not detailed. Moreover, Scandinavian cohorts typically have a higher prevalence of time in therapeutic range while taking warfarin, perhaps further curtail bleeding risk, compared with the general population.

Furthermore, rates of percutaneous coronary intervention in this postmyocardial infarction population were low (approximately 30%), despite an incidence of ST-elevation myocardial infarction (STEMI) of roughly 22%. Rates of STEMI and percutaneous coronary intervention were lower in the warfarin cohort, and associated uptake of dual antiplatelet therapy and aspirin monotherapy was also reduced in this group. Thus, relatively few patients (approximately 17%) were discharged taking triple therapy (warfarin plus dual antiplatelet therapy) after myocardial infarction, which may underestimate the overall bleeding risk in patients who were treated with warfarin after a myocardial infarction in this study compared with the general population, despite multivariable modeling.

These data stand in contrast to figures reported in contemporary US-based registries with 60% of patients treated with warfarin admitted for myocardial infarction requiring stenting and being discharged taking triple therapy.4 This study informs understanding of the prescribing patterns of warfarin in a relatively low-risk bleeding cohort, but specific ischemic and bleeding outcomes should be interpreted with caution. Limited data were provided regarding anticoagulation strategies in patients at higher risk of bleeding after myocardial infarction, including the large percentage of patients requiring dual antiplatelet therapy by current guidelines.

As the armamentarium of available oral antiplatelet and anticoagulant agents grows, specific testing of this subgroup is required to optimize combination post-myocardial infarction therapies. On balance, major bleeding may be the single most important predictor of subsequent long-term mortality, potentially surpassing risk associated with early recurrent myocardial infarction.5 The study by Carrero et al6 may provide false reassurance that warfarin therapy following myocardial infarction is without significant risk of bleeding.

Muthiah Vaduganathan, MD, MPH
Stephen J. Greene, MD

Author Affiliations: Department of Medicine, Massachusetts General Hospital, Boston (Vaduganathan); Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Greene).

Correspondence: Muthiah Vaduganathan, MD, MPH, Department of Medicine, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 (muthu@md.northwestern.edu).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Letters

June 25, 2014 Volume 311, Number 24

2541

Copyright 2014 American Medical Association. All rights reserved.